|
|
ED Treatment
Recently Added
Recent News
03/17/10 Nova Century Scientific to market and sell Diamedix’ products in Canada
IVAX Diagnostics, Inc. (AMEX:IVD), a fully integrated global invitro diagnostics company, announced that its subsidiary, Diamedix Corporation, has signed a distribution agreement with Nova Century Scientific (“Nova”), a leading Canadian distributor and manufacturer of diagnostic kits and laboratory supplies. Through this agreement, which marks IVAX Diagnostics’ entry into the Canadian market, Nova will market and sell 50 of Diamedix’s products, including analyzer instrumentation, under the Diamedix brand. Nova distributes products to hospitals, clinical laboratories and research institutions across Canada, and is a subsidiary of IMMCO Diagnostics, Inc. 03/17/10 Access MediQuip enhances Recall Management Service for implantable devices Access MediQuip, LLC, the nation's first and largest provider of outsourced implantable medical device management solutions to the healthcare industry, announced today it has enhanced its proprietary Recall Management Service, "RMS," for its customers nationwide. The new release is designed to protect patients, inform and empower surgeons and facilities, and help payers improve quality while managing cost. 03/17/10 AstraZeneca's CRESTOR: Health Canada approves new indication Approval based on JUPITER trial which demonstrated reduction of cardiovascular events by nearly half Top Category's Bestsellers
Pain ReliefPain is a physical or emotional suffering, sensation, torture, disorder and opposition to pleasure. From medicine point of view pain is the reaction to painful factor(even or object that causes pain) This reaction is distinguished by the certain emotional manifestations, reflector changes in the functions of internal organs, neuromotor instinctive reflexes and strong-willed efforts aimed to the deliverance elimination of the painful factor. Prolonged pain manifests with changes in the physiological parameters (blood pressure, pulse, dilation of pupils, changes in hormone concentration). Despite pain causes suffering,it is the most important component of the defense system of human organism. Pain gives warning of tissue damage and the development of pathologic process. Pain is also the permanent regulator of homeostatic reactions, including their highest behavioral forms. However, it does not mean that pain possesses only defense properties. Under specific circumstances, pain itself becomes the part of the pathologic process,being more dangerous than damage that caused this pain. Pain can be divided into acute and chronic. Each of these form is subdivided into several types according to whence:
Among the adult Americans in 2007 nearly 16,8% desired to cure back pain ; 6,6% - neck pains; 4,9% - arthritis; 4,9% - articulate pains; 3,1% - headache and 2,4% attempted to manage the periodically repetitive pains. Category News
03/10/10 - FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has receiv
07/06/09 - Warnings about ‘over-use’ of paracetamol
A panel of experts in the United States has raised new concerns about the popular painkiller paracetamol and are calling for the Food and Drug Administration (FDA) to reduce the maximum dose of paracetamol allowed because they say 'over-use' can cause ser
06/04/07 - Australian Medical Association Awards 2007 - The MJA Wyeth Award
The twelfth The Medical Journal of Australia/Wyeth Australia award for the best original research published in the Medical Journal of Australia was awarded during the opening ceremony of the AMA National Conference in Melbourne today.
05/23/07 - Trophos Starts Phase II Clinical Trial Of TRO19622 In Painful Diabetic Neuropathy
Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the first patients have been enrolled in a Phase IIa clinical trial of its of lead product, TRO19622. The rand |